Understanding Parallel Target Identification Efforts in the Induction of Fetal Hemoglobin

News
Video

Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what their parallel target identification efforts were able to identify, and how this identification was important in his research.

Pharmacy Times® interviewed Christopher Moxham, the senior vice president of discovery research at Fulcrum Therapeutics, on his presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into the induction of fetal hemoglobin by FTX6058, a novel small molecule development candidate.

In this video, Moxham explains what their parallel target identification efforts were able to identify, and how this identification was important in his research.

Related Videos
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
Opill manufacturing | Perrigo
Healthy food selection - Image credit: Alexander Raths | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.